With this issue of the Drug Information Journal, I mark the end of my term as Editor-in-Chief. It has been a gratifying three years. During that time, we have given the Drug Information Journal an entirely new look, which has greatly improved the organization and readability of the journal. We have also increased the geographic and professional diversity of the editorial board. It has been an enormous pleasure to work with such an esteemed and dedicated group of individuals. Finally, we have implemented rigorous manuscript review procedures, which have enhanced the quality of the articles that appear in each issue. Our goal has been to meet the varied demands of the Drug Information Journal readership and ensure that published articles meet the highest standards of scholarship and value. I believe that we have come a long way toward achieving that goal. But there is still much that can be done.
The Drug Information Journal is unique among professional journals. For one thing, the Drug Information Journal's readership is extraordinarily diverse, representing drug developers, regulators, policy-makers, service providers, marketers, consultants, and academics. Also, the journal must provide a meeting ground for a multitude of disciplines, such as pharmacology, molecular biology, medicine, law, economics, statistics, business, and public policy. In addition, the Drug Information Journal must reflect the needs of a truly multinational and geographically-expanding audience. Perhaps the greatest challenge for the Drug Information Journal, however, is to keep pace with the many dramatic scientific and technological advances in drug discovery and development, and to provide clarity and insight into the ever-changing regulatory, legal, political, and social landscape for pharmaceutical and biopharmaceutical innovation.
Few if any research and development (R&D) processes rival pharmaceutical innovation in terms of the extraordinary time, cost, risk, and complexity involved in bringing a new product to market. Today, there are two major challenges to that process. The first is the apparent decline in output by the research-based industry, brought about by increasing clinical trial size, rapidly rising R&D costs, greater regulatory demands, inefficient drug development programs, and unviable R&D strategies. The second is cost containment pressure, fueled by public restiveness and concern over skyrocketing healthcare costs and global drug price disparities. There are no simple solutions to dealing with these threats. However, an open and candid discussion of the issues, by all stakeholders, utilizing the highest quality data and analyses, will Kaitin maximize the prospect of finding the best and most productive path forward. The Drug Infor-mationJournal will continue to provide that neutral forum, in which scholarly research and ideas can be shared and discussed.
Many thanks to the Drug Information Journal editorial board, to the administrative staff at the Drug Information Association, and to all of the Drug Information Journal's readers for making my term as Editor-in-Chief a rewarding and enjoyable experience.
Kenneth I Kaitin, PhD
Editor-in-Chief
